Hood River Capital Management LLC Has $67.87 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Hood River Capital Management LLC cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 37.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 758,697 shares of the medical equipment provider's stock after selling 453,255 shares during the quarter. Hood River Capital Management LLC owned approximately 1.09% of Lantheus worth $67,873,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. grew its stake in Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after buying an additional 435,445 shares during the last quarter. Reinhart Partners LLC. boosted its stake in Lantheus by 9.9% in the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock worth $122,280,000 after purchasing an additional 123,282 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Lantheus by 2.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock worth $120,510,000 after purchasing an additional 30,891 shares during the last quarter. Swedbank AB increased its stake in shares of Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after buying an additional 385,000 shares in the last quarter. Finally, Portolan Capital Management LLC raised its holdings in shares of Lantheus by 21.1% in the fourth quarter. Portolan Capital Management LLC now owns 812,630 shares of the medical equipment provider's stock valued at $72,698,000 after buying an additional 141,749 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Price Performance

Shares of Lantheus stock traded up $0.29 on Monday, hitting $102.06. 362,891 shares of the company's stock traded hands, compared to its average volume of 953,004. Lantheus Holdings, Inc. has a one year low of $65.76 and a one year high of $126.89. The stock has a market capitalization of $6.99 billion, a PE ratio of 17.02 and a beta of 0.20. The firm's 50-day moving average price is $97.37 and its two-hundred day moving average price is $95.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on LNTH shares. Truist Financial raised their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. B. Riley dropped their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, JMP Securities reiterated a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $129.43.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 in the last quarter. Corporate insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.